E-viri
Recenzirano
Odprti dostop
-
Hasegawa, Kiyoshi; Takemura, Nobuyuki; Yamashita, Tatsuya; Watadani, Takeyuki; Kaibori, Masaki; Kubo, Shoji; Shimada, Mitsuo; Nagano, Hiroaki; Hatano, Etsuro; Aikata, Hiroshi; Iijima, Hiroko; Ueshima, Kazuomi; Ohkawa, Kazuyoshi; Genda, Takuya; Tsuchiya, Kaoru; Torimura, Takuji; Ikeda, Masafumi; Furuse, Junji; Akahane, Masaaki; Kobayashi, Satoshi; Sakurai, Hideyuki; Takeda, Atsuya; Murakami, Takamichi; Motosugi, Utaroh; Matsuyama, Yutaka; Kudo, Masatoshi; Tateishi, Ryosuke
Hepatology research, 20/May , Letnik: 53, Številka: 5Journal Article
The fifth version of the Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, according to the methodology of evidence‐based medicine and partly to the Grading of Recommendations Assessment, Development and Evaluation system, which was published in October 2021 in Japanese. In addition to surveillance–diagnostic and treatment algorithms, a new algorithm for systemic therapy has been created, as multiple drugs for hepatocellular carcinoma can be currently selected. Here, new or revised algorithms and evidence on which the recommendations are based are described.
